Why No One Has Looked for New Medicines in Rewilded Land — Until Now

When I tell people I’m researching antibiotic potential in rewilded land, they often ask the same question: “Hasn’t someone already done that?” The surprising answer is no — and that absence says a lot about how science has been organized.

For decades, ecologists and biomedical researchers worked in separate worlds. Conservation scientists measured success in biodiversity or carbon, while medical scientists searched for compounds in pristine rainforests or laboratory cultures. Few thought to look at restored landscapes, even though rewilding revives the microbial and fungal diversity that first gave us penicillin, streptomycin, and other antibiotics.

Science built silos, and rewilding is new enough that the bridges between ecology and medicine are only now being built.

The timing has finally caught up. Affordable microbial assays, portable sequencing, and growing public awareness of antibiotic resistance have created a moment of convergence. Rewilded soils are ready to be studied, and our tools are ready to study them.

What makes this research exciting is not just its novelty, but its symbolism. Rewilding shows that life, given the chance, renews itself. Perhaps medicine can too — if we’re willing to look for healing in the places we’ve only just begun to restore.